New ADHD Research to be Presented This Fall
New research aims to provide adults and children with ADHD with better insights into their treatment and daily care.
Updated on Oct. 21, 2026 in Autism
Live Poll
Do you feel current ADHD management options address the daily practical challenges families face?
Collegium Pharmaceutical is set to present seven new research abstracts on ADHD treatment and patient care at two major scientific conferences this fall. These findings include real-world data and studies aimed at improving the daily management of the condition for the 22.5 million affected individuals in the United States.
Why it matters
Understanding the lived experience and long-term treatment outcomes of ADHD is critical for developing more effective clinical support strategies. This new research focuses on broadening the understanding of specific needs across various age groups and settings to improve quality of life.
The seven abstracts include Phase 4 clinical studies of AZSTARYS in children, retrospective real-world analyses of JORNAY PM in adults, and survey research regarding caregivers. These studies provide evidence from both clinical trials and routine practice, though specific results remain pending presentation.
The players
Collegium Pharmaceutical
A pharmaceutical company that focuses on the development and commercialization of treatments for pain and central nervous system disorders, including ADHD.
The details
The research employs a mix of methodologies, ranging from retrospective real-world data analyses to patient and caregiver surveys. By examining routine clinical practice alongside Phase 4 studies, the research seeks to offer insight into how existing ADHD treatment regimens function in diverse, real-world environments. This approach aims to address gaps in understanding the daily functional needs of patients across pediatric and adult populations.
Timeline
The American Academy of Child and Adolescent Psychiatry 2026 Annual Meeting takes place in Atlanta from October 26 to October 31, 2026.
The Neuroscience Education Institute Fall Congress takes place in Colorado Springs from November 5 to November 8, 2026.
Health Landscape
This research continues the ongoing effort to refine ADHD management strategies, which has evolved from focusing solely on symptom control to incorporating comprehensive patient and caregiver quality-of-life metrics. It aligns with broader clinical efforts to optimize treatment plans for the millions of Americans navigating this neurodevelopmental condition.
As new clinical data emerges, individuals managing ADHD should continue to track how their current treatment plan impacts their daily functioning and quality of life. These observations are important points to bring to your physician during your next scheduled appointment to ensure your care plan remains effective.
The takeaway
These upcoming presentations underscore the importance of integrating patient-centered data into clinical decision-making. Keep a symptom log or record of your daily treatment experience to discuss with your healthcare provider, as real-world patient input remains a vital part of medical care.
Further reading
For broader information on the evolving standards for managing neurodevelopmental needs, see the Autism section.
Live Poll
Do you feel current ADHD management options address the daily practical challenges families face?
